Vital Therapies, Inc. (NASDAQ:VTL) has received a consensus rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $10.00.

VTL has been the topic of several analyst reports. Raymond James Financial restated a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st.

Shares of Vital Therapies (NASDAQ:VTL) opened at $5.95 on Tuesday. Vital Therapies has a 1 year low of $2.25 and a 1 year high of $6.50.

Vital Therapies (NASDAQ:VTL) last posted its earnings results on Wednesday, October 25th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. During the same period last year, the firm earned ($0.32) earnings per share. analysts forecast that Vital Therapies will post -1.26 EPS for the current fiscal year.

In related news, Director Muneer A. Satter acquired 100,000 shares of Vital Therapies stock in a transaction dated Wednesday, December 13th. The stock was acquired at an average cost of $5.48 per share, with a total value of $548,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Muneer A. Satter acquired 50,000 shares of Vital Therapies stock in a transaction dated Thursday, December 7th. The shares were bought at an average cost of $4.77 per share, with a total value of $238,500.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 300,000 shares of company stock valued at $1,520,000. 32.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its stake in shares of Vital Therapies by 0.9% during the 3rd quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock worth $13,145,000 after acquiring an additional 23,810 shares in the last quarter. Granahan Investment Management Inc. MA boosted its stake in shares of Vital Therapies by 51.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after acquiring an additional 131,828 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after acquiring an additional 168,705 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Vital Therapies during the 2nd quarter worth $396,000. Finally, Blair William & Co. IL boosted its stake in shares of Vital Therapies by 67.2% during the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after acquiring an additional 40,000 shares in the last quarter. 24.35% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Vital Therapies, Inc. (VTL) Receives Average Rating of “Hold” from Brokerages” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/vital-therapies-inc-vtl-receives-average-rating-of-hold-from-brokerages/1772156.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.